ClinicalTrials.gg
RecruitingNCT07944482Updated Nov 18, 2026

A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal Liver Function

A Phase 1 interventional study of GST-HG141 in Chronic Hepatitis b, sponsored by Fujian Akeylink Biotechnology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fujian Akeylink Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2026, registered Nov 2026).
  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 377 studies in Hepatitis B, Chronic with a site in China — 90 open to participants now, 111 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
252nd of 274
24 · median 120
Started
2026
with 27 others
Phase 1
51 of 377
17 open now
Primary completion
2026-12
later than 41 of 110 live
Registered
377th of 377
by date

Among the 377 studies in Hepatitis B, Chronic with a site in China, this one is the 252nd largest by planned enrollment of the 274 interventional ones that give a count, is one of 28 that started in 2026, is one of 51 in phase 1, reaches primary completion later than 41 of the 110 other live ones, and was the 377th registered.

Hepatitis B, Chronic

898 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

90 of the 377 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 90 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, non-randomized, open-label, parallel-group, single-dose study designed to evaluate the pharmacokinetic profiles and safety of GST-HG141 tablets in participants with hepatic impairment.

03

Conditions studied

  • Chronic Hepatitis b

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following inclusion criteria to be enrolled in this study.

  1. Participants aged 18 to 65 years (inclusive, as of the date of signing the form), male or female;
  2. Body weight at screening: ≥ 50 kg for males and ≥ 45 kg for females; (BMI) ranging from 18.0 to 30.0 kg/m² (inclusive of 18.0 and 30.0);
  3. Voluntarily agree to participate and provide written informed consent, and comply with the study treatment plan and visit schedule;
  4. Participants (including their partners) agree to have no childbearing plan and voluntarily use effective measures from screening until 3 months after administration of the product, and have no plan to donate sperm or oocytes;
  5. Estimated (eGFR, calculated by the CKD-EPI 2021 equation) ≥ 60 mL/(min·1.73 m²).

    Participants with normal hepatic function must additionally meet all of the following criteria:

  6. Demographic and baseline means of participants in the normal hepatic function group (Group C) at screening must satisfy the following matching criteria:

    1. Body weight matched with the hepatic impairment groups (Group A + Group B), with a mean difference within ±10 kg;
    2. Age matched with the hepatic impairment groups (Group A + Group B), with a mean difference within ±10 years;
    3. Gender distribution matched with the hepatic impairment groups (Group A + Group B), with a difference in number within ±1 subject.

    Participants with hepatic impairment must additionally meet all of the following criteria:

  7. Previously diagnosed with liver cirrhosis via liver or other medical imaging techniques (including laparoscopy, computed tomography [CT], magnetic resonance imaging [MRI], or ultrasound), with a disease duration of ≥6 months and stable disease status (judged by the investigator based on the participant's condition) for ≥4 weeks; without albumin administration within 14 days, classified as Class A or B based on Child-Pugh score (grade of encephalopathy, ascites, serum albumin, serum , and seconds of prolonged );
  8. Except for hepatic insufficiency and its complications, the investigator judges the participant's general medical condition to be acceptable based on medical history inquiry, physical examination, vital signs, laboratory tests (routine blood test, blood biochemistry, coagulation function, routine urine test), AFP, 12-lead , chest anteroposterior radiograph, B-ultrasound, etc.;
  9. No medication for at least 14 days prior to dosing of the investigational product, or on a stable medication regimen for the treatment of hepatic impairment, its complications, and other concomitant diseases, with no changes to medication (including drug type, dosage, or frequency of administration) within 14 days prior to dosing of the investigational product.
  10. Participants with chronic shall have stable disease, with no evidence of acute hepatitis exacerbation or acute hepatic decompensation; and any antiviral therapy must have been administered stably for at least 4 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

For all participants:

  1. Participants with allergic constitution, including those with a known history of allergy to two or more types of foods and drugs, or a known previous allergic reaction to the active ingredients or of GST-HG141 Tablets;
  2. Participants who have undergone major surgery (excluding diagnostic surgery) within 6 months prior to screening, plan to receive surgery during the study period, or have received surgery judged by the investigator to affect safety evaluation or drug absorption, distribution, metabolism and excretion;
  3. Participants who develop an acute disease within 2 weeks before dosing, which is judged by the investigator to affect safety evaluation or drug absorption, distribution, metabolism and excretion;
  4. Participants with a history of infectious diseases within 4 weeks prior to screening (conditions that may significantly affect the safety evaluation of participants as assessed by the investigator);
  5. Participants who have received vaccination within 30 days prior to screening or plan to receive vaccination during the study period;
  6. Participants with positive (HIV) or syphilis test results at screening;
  7. Participants with frequent alcohol consumption within 3 months prior to screening, defined as an average weekly alcohol intake exceeding 14 alcohol units (1 unit = 360 mL beer with 5% alcohol content, or 45 mL spirits with 40% alcohol content, or 150 mL wine with 12% alcohol content); those who cannot refrain from all alcoholic products during the trial; or those with a positive alcohol breath test;
  8. Participants with an average daily cigarette consumption of ≥ 5 cigarettes within 3 months prior to screening, or those who refuse to stop using all tobacco products during the trial;
  9. Participants who consume caffeine-containing foods or beverages (e.g., coffee, tea, chocolate, caffeinated carbonated drinks, cola), grapefruit, grapefruit juice or poppy-containing foods within 24 hours before dosing and cannot discontinue such intake during the trial; those who cannot avoid strenuous exercise from 24 hours before dosing throughout the trial period;
  10. Participants with difficulty in swallowing tablets, or those with special dietary restrictions who cannot accept unified meals;
  11. Participants with difficulty in venous blood collection or a history of needle or blood phobia;
  12. Participants who have donated blood or had a total blood loss of ≥ 400 mL within 3 months prior to screening, or plan to donate blood during the study period and within 1 month after the final follow-up;
  13. Participants with a history of gastrointestinal diseases (including active conditions) affecting drug absorption from 1 year prior to screening up to enrollment, including those with severe (assessed by the investigator) or active upper gastrointestinal diseases, active gastrointestinal bleeding, or a history of gastrointestinal surgery.
  14. Participants with a history of drug abuse (including non-medical use of narcotic drugs and psychotropic substances) within 1 year prior to screening to enrollment, or with positive urine drug screening results (including morphine, methamphetamine, ketamine, MDMA, tetrahydrocannabinolic acid, etc.);
  15. Participants deemed unsuitable for participation by the investigator, or those who request to withdraw from the trial on their own initiative;
  16. Participants diagnosed with or hepatitis D.

    For female participants (in addition to the above criteria, those meeting any of the following shall also be excluded):

  17. Participants who used oral within 30 days prior to screening to enrollment;
  18. Participants who received long-acting estrogen or progestogen injections (including progestogen-only intrauterine devices) or implantable contraceptives within 6 months prior to screening to enrollment;
  19. Participants who had unprotected sexual intercourse with their partners within 14 days prior to screening to enrollment;
  20. Participants with a positive pregnancy test;
  21. Pregnant or lactating women.

    For participants with hepatic impairment (excluded if meeting any of the following criteria):

  22. Cirrhosis patients with any of the following conditions deemed inappropriate by the investigator: drug-induced liver injury, history of liver transplantation, liver failure, hepatocellular carcinoma (excluding Barcelona Clinic Liver Cancer Stage 0 or patients with curative treatment outcomes), hepatorenal syndrome, active Grade 3 or 4 hepatic encephalopathy, or complications such as esophagogastric variceal rupture and bleeding occurring within 3 months prior to screening;
  23. Participants with active syphilis (positive treponema pallidum antibody plus positive TRUST/RPR), active (anti-HCV positive with HCV RNA above the normal reference range), or active hepatitis B (HBsAg positive with HBVDNA above the normal reference range) at screening;
  24. Participants with drug-induced liver injury or acute liver injury caused by any other etiology;
  25. Participants with severe ascites and/or pleural effusion (exceptions may be granted for participants with stable physical conditions as judged by the investigator);
  26. Participants with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg at screening (enrollment is permitted if blood pressure is stably controlled with medication for at least one week as assessed by the investigator);
  27. Participants with biliary tract obstruction;
  28. Participants suffering from other severe systemic organ diseases at screening in addition to primary liver diseases, including but not limited to gastrointestinal, respiratory, renal, neurological, hematological, endocrine, neoplastic, immune, psychiatric, cardiovascular and cerebrovascular diseases, and judged by the investigator to be ineligible for this trial;
  29. Participants with any of the following laboratory abnormalities at screening: (a) (ALT) or aspartate transaminase (AST) > 5× (one repeat test is allowed); (b) serum alpha-fetoprotein (AFP) > 20 ng/mL;
  30. Participants who have taken concomitant medications that may interact with the study drug within 2 weeks before dosing, including inhibitors and inducers of and P-gp ;
  31. Participants who have used albumin within 1 month prior to screening;
  32. Participants who have participated in any clinical trial within 1 month prior to screening, or are still within 7 half-lives of other drugs at screening (whichever is longer), or plan to participate in other clinical trials during this study.

    For healthy participants (excluded if meeting any of the following criteria):

  33. Participants with abnormal findings in vital sign examination, physical examination, clinical laboratory tests (routine blood test, routine urine test, blood biochemistry, coagulation function), infectious disease screening, 12-lead , abdominal color ultrasound and chest anteroposterior radiograph at screening, as judged by the investigator;
  34. Participants with a history of chronic or severe diseases involving the cardiovascular, hepatic, renal, biliary, respiratory, hematologic and lymphatic, endocrine, immune, psychiatric, neuromuscular, or gastrointestinal systems from 1 year prior to screening up to enrollment, which are judged clinically significant by the investigator.
  35. Participants with clinically significant abnormal electrocardiogram results during the screening period;
  36. Participants who have taken any prescription drugs, over-the-counter drugs, health supplements, vitamins, Chinese herbal medicines and other products within 14 days prior to screening;
  37. Participants who have used other investigational drugs within 3 months prior to screening or plan to participate in other clinical trials during this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Part A

    mild hepatic impairment

    Drug: GST-HG141

  • Experimental
    Part B

    moderate hepatic impairment

    Drug: GST-HG141

  • Experimental
    Part C

    healthy participants

    Drug: GST-HG141

Interventions

  • GST-HG141 will be administered as a single oral dose on the morning of day 1

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) for GST-HG141

    Maximum observed plasma GST-HG141 concentration.

    Time frame: up to 6 days

Secondary outcomes

  1. AEs

    To evaluate the safety and tolerability of GST-HG141 tablets

    Time frame: up to 11 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 74 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 5 months is below that.

Counting every sponsor, half of 82 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 18, 2026
StartActual
Jul 3, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07944482
Lead sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jul 3, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Chuanjing Li
Contact
lichuanjing@akeylink.cn
18844146643

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neracorvir

Start the discussion